Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade
Virginia Pascual, Florence Allantaz, Edsel Arce, Marilynn Punaro, Jacques Banchereau, Virginia Pascual, Florence Allantaz, Edsel Arce, Marilynn Punaro, Jacques Banchereau
Abstract
Systemic onset juvenile idiopathic arthritis (SoJIA) encompasses approximately 10% of cases of arthritis that begin in childhood. The disease is unique in terms of clinical manifestations, severity of joint involvement, and lack of response to tumor necrosis factor blockade. Here, we show that serum from SoJIA patients induces the transcription of innate immunity genes, including interleukin (IL)-1 in healthy peripheral blood mononuclear cells (PBMCs). Upon activation, SoJIA PBMCs release large amounts of IL-1beta. We administered recombinant IL-1 receptor antagonist to nine SoJIA patients who were refractory to other therapies. Complete remission was obtained in seven out of nine patients and a partial response was obtained in the other two patients. We conclude that IL-1 is a major mediator of the inflammatory cascade that underlies SoJIA and that this cytokine represents a target for therapy in this disease.
Figures
References
- Cassidy, J.T., and R.E. Petty. 2001. Textbook of Pediatric Rheumatology. W.B. Saunders, Philadelphia, PA. 976 pp.
- Wallace, C.A., and J.E. Levinson. 1991. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum. Dis. Clin. North Am. 17:891–905.
- Ravelli, A., and A. Martini. 2003. Early predictors of outcome in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 21:S89–S93.
- Modesto, C., P. Woo, J. Garcia-Consuegra, R. Merino, M. Garcia-Granero, C. Arnal, and A.M. Prieur. 2001. Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involvement as markers for a bad prognosis. Clin. Exp. Rheumatol. 19:211–217.
- Ravelli, A. 2004. Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 22:271–275.
- Spiegel, L.R., R. Schneider, B.A. Lang, N. Birdi, E.D. Silverman, R.M. Laxer, D. Stephens, and B.M. Feldman. 2000. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum. 43:2402–2409.
- Lomater, C., V. Gerloni, M. Gattinara, J. Mazzotti, R. Cimaz, and F. Fantini. 2000. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol. 27:491–496.
- Bowyer, S.L., P.A. Roettcher, G.C. Higgins, B. Adams, L.K. Myers, C. Wallace, R. Rennebohm, T.L. Moore, P.H. Pepmueller, C. Spencer, et al. 2003. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J. Rheumatol. 30:394–400.
- de Benedetti, F., M. Massa, P. Robbioni, A. Ravelli, G.R. Burgio, and A. Martini. 1991. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 34:1158–1163.
- Adebajo, A.O., and M.A. Hall. 1998. The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. Br. J. Rheumatol. 37:1240–1242.
- Lehman, T.J. 2000. Clinical trials for the treatment of systemic onset juvenile rheumatoid arthritis-juvenile idiopathic arthritis. Curr. Rheumatol. Rep. 2:313–315.
- Lehman, T.J., K.H. Striegel, and K.B. Onel. 2002. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J. Pediatr. 140:125–127.
- Lovell, D.J., E.H. Giannini, A. Reiff, G.D. Cawkwell, E.D. Silverman, J.J. Nocton, L.D. Stein, A. Gedalia, N.T. Ilowite, C.A. Wallace, et al. 2000. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342:763–769.
- Lovell, D.J., E.H. Giannini, A. Reiff, O.Y. Jones, R. Schneider, J.C. Olson, L.D. Stein, A. Gedalia, N.T. Ilowite, C.A. Wallace, et al. 2003. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 48:218–226.
- Horneff, G., H. Schmeling, T. Biedermann, I. Foeldvari, G. Ganser, H.J. Girschick, T. Hosbach, H.I. Huppertz, R. Keitzer, R.M. Kuester, et al. 2004. The German etanercept registry for treatment of juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 63:1638–1644.
- Quartier, P., P. Taupin, F. Bourdeaut, I. Lemelle, P. Pillet, M. Bost, J. Sibilia, I. Kone-Paut, S. Gandon-Laloum, M. LeBideau, et al. 2003. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 48:1093–1101.
- Blanco, P., A.K. Palucka, M. Gill, V. Pascual, and J. Banchereau. 2001. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 294:1540–1543.
- Bennett, L., A.K. Palucka, E. Arce, V. Cantrell, J. Borvak, J. Banchereau, and V. Pascual. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197:711–723.
- Moser, B., M. Wolf, A. Walz, and P. Loetscher. 2004. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25:75–84.
- Saeki, T., and A. Naya. 2003. CCR1 chemokine receptor antagonist. Curr. Pharm. Des. 9:1201–1208.
- Andrei, C., P. Margiocco, A. Poggi, L.V. Lotti, M.R. Torrisi, and A. Rubartelli. 2004. Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: implications for inflammatory processes. Proc. Natl. Acad. Sci. USA. 101:9745–9750.
- Shoham, N.G., M. Centola, E. Mansfield, K.M. Hull, G. Wood, C.A. Wise, and D.L. Kastner. 2003. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl. Acad. Sci. USA. 100:13501–13506.
- Aksentijevich, I., M. Nowak, M. Mallah, J.J. Chae, W.T. Watford, S.R. Hofmann, L. Stein, R. Russo, D. Goldsmith, P. Dent, et al. 2002. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46:3340–3348.
- Hawkins, P.N., H.J. Lachmann, E. Aganna, and M.F. McDermott. 2004. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 50:607–612.
- Hoffman, H.M., S. Rosengren, D.L. Boyle, J.Y. Cho, J. Nayar, J.L. Mueller, J.P. Anderson, A.A. Wanderer, and G.S. Firestein. 2004. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet. 364:1779–1785.
- Dinarello, C.A. 2002. The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol. 20:S1–13.
- Saijo, S., M. Asano, R. Horai, H. Yamamoto, and Y. Iwakura. 2002. Suppression of autoimmune arthritis in interleukin-1–deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum. 46:533–544.
- Horai, R., S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, and Y. Iwakura. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist–deficient mice. J. Exp. Med. 191:313–320.
- Genovese, M.C., S. Cohen, L. Moreland, D. Lium, S. Robbins, R. Newmark, and P. Bekker. 2004. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50:1412–1419.
- Buch, M.H., S.J. Bingham, Y. Seto, D. McGonagle, V. Bejarano, J. White, and P. Emery. 2004. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. Arthritis Rheum. 50:725–728.
- Muller, K., E.B. Herner, A. Stagg, K. Bendtzen, and P. Woo. 1998. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br. J. Rheumatol. 37:562–569.
- Muzaffer, M.A., J.M. Dayer, B.M. Feldman, W. Pruzanski, P. Roux-Lombard, R. Schneider, R.M. Laxer, and E.D. Silverman. 2002. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. J. Rheumatol. 29:1071–1078.
- Verbsky, J.W., and A.J. White. 2004. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 31:2071–2075.
- Cassidy, J.T., J.E. Levinson, J.C. Bass, J. Baum, E.J. Brewer Jr., C.W. Fink, V. Hanson, J.C. Jacobs, A.T. Masi, J.G. Schaller, et al. 1986. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum. 29:274–281.
Source: PubMed